Management of post‐transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS Guidelines

Summary A joint working group established by the Haemato‐oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Transplantation Society (BTS) has reviewed the available literature and made recommendations for the diagnosis and management of post‐transplant lym...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2010-06, Vol.149 (5), p.693-705
Main Authors: Parker, Anne, Bowles, Kristin, Bradley, J. Andrew, Emery, Vincent, Featherstone, Carrie, Gupte, Girish, Marcus, Robert, Parameshwar, Jayan, Ramsay, Alan, Newstead, Charles
Format: Article
Language:English
Subjects:
Adult
Algorithms
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents - therapeutic use
Biological and medical sciences
chemotherapy
Combined Modality Therapy
Drug Administration Schedule
Evidence-Based Medicine - methods
Hematologic and hematopoietic diseases
Humans
Immunosuppressive Agents - administration & dosage
Immunosuppressive Agents - adverse effects
Immunotherapy, Adoptive - methods
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
lymphoproliferative
Lymphoproliferative Disorders - etiology
Lymphoproliferative Disorders - therapy
Medical sciences
Organ Transplantation - adverse effects
Prognosis
Reoperation
Rituximab
therapy
transplant
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary A joint working group established by the Haemato‐oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Transplantation Society (BTS) has reviewed the available literature and made recommendations for the diagnosis and management of post‐transplant lymphoproliferative disorder in adult recipients of solid organ transplants. This review details the therapeutic options recommended including reduction in immunosuppression (RIS), transplant organ resection, radiotherapy and chemotherapy. Effective therapy should be instituted before progressive disease results in declining performance status and multi‐organ dysfunction. The goal of treatment should be a durable complete remission with retention of transplanted organ function with minimal toxicity.
ISSN:0007-1048
1365-2141
DOI:10.1111/j.1365-2141.2010.08160.x